Mitochondrial and Clearance Impairment in p.D620N VPS35 Patient-Derived Neurons
File version
Version of Record (VoR)
Author(s)
Larsen, Simone B
Antony, Paul
Mencke, Pauline
Massart, Francois
Jarazo, Javier
Schwamborn, Jens C
Barbuti, Peter A
Mellick, George D
Kruger, Rejko
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
Size
File type(s)
Location
Abstract
Background: VPS35 is part of the retromer complex and is responsible for the trafficking and recycling of proteins implicated in autophagy and lysosomal degradation, but also takes part in the degradation of mitochondrial proteins via mitochondria-derived vesicles. The p.D620N mutation of VPS35 causes an autosomal-dominant form of Parkinson's disease (PD), clinically representing typical PD. Objective: Most of the studies on p.D620N VPS35 were performed on human tumor cell lines, rodent models overexpressing mutant VPS35, or in patient-derived fibroblasts. Here, based on identified target proteins, we investigated the implication of mutant VPS35 in autophagy, lysosomal degradation, and mitochondrial function in induced pluripotent stem cell-derived neurons from a patient harboring the p.D620N mutation. Methods: We reprogrammed fibroblasts from a PD patient carrying the p.D620N mutation in the VPS35 gene and from two healthy donors in induced pluripotent stem cells. These were subsequently differentiated into neuronal precursor cells to finally generate midbrain dopaminergic neurons. Results: We observed a decreased autophagic flux and lysosomal mass associated with an accumulation of α-synuclein in patient-derived neurons compared to controls. Moreover, patient-derived neurons presented a mitochondrial dysfunction with decreased membrane potential, impaired mitochondrial respiration, and increased production of reactive oxygen species associated with a defect in mitochondrial quality control via mitophagy. Conclusion: We describe for the first time the impact of the p.D620N VPS35 mutation on autophago-lysosome pathway and mitochondrial function in stem cell-derived neurons from an affected p.D620N carrier and define neuronal phenotypes for future pharmacological interventions. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Journal Title
Movement Disorders
Conference Title
Book Title
Edition
Volume
36
Issue
3
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
© The Author(s) 2021. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permitsuse and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifcations or adapta-tions are made.
Item Access Status
Note
Access the data
Related item(s)
Subject
Clinical sciences
Sports science and exercise
Neurosciences
Science & Technology
Life Sciences & Biomedicine
Clinical Neurology
VPS35
Neurology
Persistent link to this record
Citation
Hanss, Z; Larsen, SB; Antony, P; Mencke, P; Massart, F; Jarazo, J; Schwamborn, JC; Barbuti, PA; Mellick, GD; Kruger, R, Mitochondrial and Clearance Impairment in p.D620N VPS35 Patient-Derived Neurons, Movement Disorders, 2020, 36 (3), pp. 704-715